Purpose: Extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE) are among the major threats to global health because of their encoded protection against key antibiotics.

Methods: A comparative cross-sectional study was conducted among oncology and non-oncology patient groups (1:1; n = 214) on a consecutive sampling approach. Stool or rectal swab was collected from June 2021 to November 2021 and screened for ESBL-PE and CPE using ChromID-ESBL media. Confirmation for the enzymes was made by using combination disc and modified carbapenem inactivation methods, respectively. Disk diffusion method was used to determine antimicrobial susceptibility testing following the recommendations of CLSI 2022. SPSS software version 23 was used for data analysis.

Results: Fecal carriage prevalence of ESBL-PE was found in 90 (84.1%) of oncology participants and in 77 (71.9%) of non-oncology patients (p = 0.032). Escherichia coli was the most common ESBL-PE isolate in 82 (62.5%) and 68 (88.3%) of oncology and non-oncology patients, followed by Klebsiella oxytoca [15 (11.5%) versus 6 (7.8%)], respectively. Out of the total ESBL-PE isolates from both oncology and non-oncology patient groups, the maximum level of resistance was observed against ciprofloxacin 177 (86.3%), trimethoprim-sulfamethoxazole 103 (80.3%), tetracycline 97 (75.8%), whereas enhanced susceptibility was appreciated to tigecycline 200 (97.6%), meropenem 162 (79.0%), and ertapenem 145 (70.7%) with no significant difference between oncology and non-oncology group. Carbapenemase-producing isolates from oncology patients were 12 (11.2%), whereas it was 4 (3.7%) (p = 0.611) from non-oncology group. Bacterial isolates from oncology in this study showed a trend of multiple drug resistance of 113 (88.3%).

Conclusion: The results revealed alarmingly high carriage rates of ESBL and CPE among all study participants. Moreover, the isolates showed increased resistance rates to alternative drugs and had multiple antibiotic-resistant patterns. Hence, it is important to emphasize strict adherence to antimicrobial stewardship program as well as infection prevention and control practices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625765PMC
http://dx.doi.org/10.2147/CMAR.S422376DOI Listing

Publication Analysis

Top Keywords

oncology non-oncology
20
non-oncology patients
12
isolates oncology
12
fecal carriage
8
extended-spectrum β-lactamase
8
carbapenemase-producing enterobacteriaceae
8
oncology
8
comparative cross-sectional
8
cross-sectional study
8
non-oncology patient
8

Similar Publications

Noninvasive Ultra Low Intensity Light Photodynamic Treatment of Glioblastoma with Drug Augmentation: LoGlo PDT Regimen.

Brain Sci

November 2024

Neurosurgery Department-Neuro-Oncology, Instituto de Neurologia de Curitiba, Rua Jeremias Maciel Perretto, 300-Campo Comprido, Curitiba 81210-310, Brazil.

This paper presents the basis for LoGlo PDT, a new treatment for glioblastoma. Glioblastoma is currently treated with maximal safe resection, temozolomide, and ionizing irradiation. Mortality in 2024 remains over 80% within several years from diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • The FDA's Accelerated Approval (AA) pathway has been used more frequently from 2015 to 2022, with 156 drug-indication pairs receiving approval amidst ongoing debates about its efficacy.
  • Pre-approval studies showed a trend towards single-arm designs with a majority being small-scale, while post-approval studies initially decreased in rigor before rebounding in later years.
  • The data indicates notable trends, including variations in study designs and participant numbers over the years, suggesting shifts in the FDA's approach to drug approval.
View Article and Find Full Text PDF

Introduction And Objectives: The increasing participation of radiologists in multidisciplinary boards brings about advantages, challenges and specific needs. The aim of this paper is to identify the boards in which radiologists participate and to detect the needs, problems and opportunities that these boards pose for our specialty.

Methods And Materials: The Spanish Society of Medical Radiology (SERAM) conducted an ad-hoc survey that was distributed among members and through social networks.

View Article and Find Full Text PDF

Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products.

Clin Pharmacol Ther

December 2024

Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA.

Article Synopsis
  • Cell and gene therapies (CGTs) have shown potential for treating hard-to-treat conditions, but their development is risky for pharmaceutical companies due to uncertainties in clinical trials and regulatory approval.
  • An analysis of CGT products from 1993 to 2023 found that only 5.3% received regulatory approval, with higher chances for products with orphan designation and lower chances for oncology-related therapies.
  • Both CAR T cell therapies and AAV gene therapies showed a similar approval likelihood of 13.6%, highlighting that approval rates vary by product type and therapeutic indication.
View Article and Find Full Text PDF

Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy.

Tissue Cell

December 2024

Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population within the tumor that have recently come into the spotlight. By extracellular matrix (ECM) remodeling and robust cross-talk with cancer cells via different secretions such as cytokines, chemokines, and growth factors, CAFs contribute to cancer progression and poorer prognoses in patients. Novel candidates have been developed to inhibit CAFs; however, due to safety and efficacy issues, none have successfully passed clinical trials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!